New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: ...

BioVie Inc. (NASDAQ: BIVI) ('BioVie” or the 'Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of ...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson’s disease has been accepted for presentation ...

Week-48 suppression was 91.8% with DOR/ISL vs 90.6% with BIC/FTC/TAF, with few discontinuations for inefficacy and similar overall tolerability. EMBRACE reported 12-month suppression rates of 94% (IV ...

The MarketWatch News Department was not involved in the creation of this content. BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- COMSOL, an independently-owned global leader in modeling and ...

Building on the recent U.S. FDA Fast Track Designation for AJ201 (Rosolutamide) and encouraging Phase 2 clinical results, AnnJi presented two scientific abstracts spanning translational transcriptomic ...

Produced by SAF Magazine and organized by BBI International in Collaboration with CAAFI TACOMA, WA, UNITED STATES, ...

ORLANDO, Fla., March 12, 2026 /PRNewswire/ -- M-tron Industries, Inc. (NYSE American: MPTI) ("Mtron" or the "Company"), a U.S.-based designer and manufacturer of highly-engineered electronic ...

Detailed price information for Benitec Biopharma Ltd ADR (BNTC-Q) from The Globe and Mail including charting and trades.

CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and ...

Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -- Oral ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...